• Type: observation (subtype: gate-fired + posture-reset)
• event_id: 2026-06-26-biotech-capital-cycle-eow-gate-fired
• Source: 2026-06-26-biotech-scan; 2026-06-26-etf-universe; perspective data table (2026-06-26).

Gate fired (domino #1): XBI RSI 76.2, near ATH, +35.6% vs VWAP. IBB RSI 74.1. LABU RSI 77.1 (+130.5% vs VWAP, parabolic). The half-open gate from the 2026-06-04 open and the 2026-06-16 update is now fully open — the biotech funding-cycle re-rate is confirmed and in the ETF price.

Ratification gate fired: TMO RSI 66.5 +12.6% 30d, DHR RSI 69.3 +13.3% 30d, MEDP RSI 77 +23.1% 30d, RGEN RSI 71.8 +29.9% 30d, IQV RSI 63.7 +15.4% 30d. The thesis's stated confirmation condition (mega-cap laggards positive 3M + RSI>60 together) has met — all five names qualify. The "laggard quality" phase of the thesis captured. TWST RSI 79.5 +55.6% 30d, ABCL RSI 73.5 +35.7% 30d (near ATH).

Domino board ticks: #0 done, #1 fired, #2 in-progress, #3 pending Q2 print, #4 running, #5 early (RGEN already moving despite being "last domino").

Posture reset: the "laggard quality" entry geometry (TMO ~$460, MEDP ~$430, RGEN ~$115) is gone. Thesis is in the price across the board. Do not add at current RSIs (66-79 across the lane). Next entry window requires XBI to pull back to RSI 55-65 and the laggards to reset to SMA20 territory. ABCL near ATH = protect-gains posture, not add-on-weakness.

SpaceX digestion window post-mortem: lasted ~3 weeks (June 12 to late June), shorter than the 4-8 week worst-case estimate. SPCX's institutional skepticism absorbed retail attention while biotech re-rated underneath. The cross-thesis timing prediction (digestion window closes, then biotech re-opens) was directionally correct; the timeline compressed.

Next gate: MEDP Q2 print (~late July) — the book-to-bill and forward guidance test whether the cycle is sustaining or one-time. If MEDP reaffirms +20%+ YoY and book-to-bill >1.2, the cycle is confirmed sustaining. If it disappoints on a fully-priced RSI 77 stock, the consolidation is sharp.